Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Luye Pharma Group Ltd.)"
Count: 45
Selected: 0
| NCT ID | Title |
|---|
| NCT03785652 | Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD) | ||
| NCT04045678 | A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease | ||
| NCT04044547 | A Study of LY03003 in Patients With Early-stage Parkinson's Disease | ||
| NCT04973735 | A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects | ||
| NCT03427853 | A Study to Evaluate the Denosumab in Healthy Adults | ||
| NCT04973722 | A Study to Evaluate LY06006 and Prolia in Healthy Adults | ||
| NCT04572698 | A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD） | ||
| NCT05060406 | A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture | ||
| NCT04198636 | A Study to Evaluate LY01011 and Xgeva® in Healthy Adults | ||
| NCT03844438 | A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors | ||
| NCT04572685 | Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients | ||
| NCT05321602 | Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder | ||
| NCT05238701 | A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects | ||
| NCT05140512 | Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® | ||
| NCT05110170 | Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® | ||
| NCT04922593 | Relative Bioavailability of LY03010 Compared to Listed Drug | ||
| NCT04859569 | Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors | ||
| NCT04853407 | A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD) | ||
| NCT04638491 | Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients | ||
| NCT04630860 | A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD | ||
| NCT04629404 | A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients | ||
| NCT04627155 | A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003 | ||
| NCT04593511 | to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers | ||
| NCT04571164 | A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD | ||
| NCT04563936 | Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® | ||
| NCT04384666 | A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers | ||
| NCT04381910 | Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer | ||
| NCT04088604 | Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors | ||
| NCT03822065 | A Relative Bioavailability Food Effect Study of LY03005 | ||
| NCT03751488 | A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients | ||
| NCT03733574 | A Study of LY03005 vs Pristiq | ||
| NCT03733561 | A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro | ||
| NCT03589066 | Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease | ||
| NCT03533127 | A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer | ||
| NCT03450109 | A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer | ||
| NCT03357796 | Relative Bioavailability (RBA) Study of LY03005 vs Pristiq® | ||
| NCT02988024 | Pilot BA Study of New LY03005 vs Pristiq | ||
| NCT02728947 | Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease | ||
| NCT02603770 | Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers | ||
| NCT02271412 | Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005 | ||
| NCT02186769 | An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder | ||
| NCT02091388 | Bioavailability of LY03004 and Risperdal® Consta® | ||
| NCT02055300 | Safety, Tolerability and Pharmacokinetics Study of LY03005 | ||
| NCT02055287 | Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder | ||
| NCT02055274 | Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease |
